Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus MICONAZOLE 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus MICONAZOLE 7.
DIFLUCAN vs MICONAZOLE 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Primarily fecal (~50%) and renal (~<1% unchanged)
Category C
Category A/B
Antifungal
Antifungal